Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago
🌐 বাংলায় দেখুন

Indications

Gout

Feluric tablets are used for the long-term control of high uric acid levels (hyperuricemia) in people with gout. They are not intended for treating hyperuricemia that has no accompanying symptoms.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Febuxostat is a non-purine medicine that works by selectively blocking an enzyme called xanthine oxidase. This enzyme is normally responsible for breaking down hypoxanthine into xanthine, and then xanthine into uric acid. By inhibiting xanthine oxidase, febuxostat reduces the body's production of uric acid, thereby lowering serum uric acid levels. At the doses used for treatment, it is not expected to affect other enzymes involved in the synthesis and breakdown of purines and pyrimidines.

Pregnancy & Breastfeeding

Pregnancy Category C. No adequate, well-controlled studies have looked at Febuxostat's use in pregnant women, so it should only be given during pregnancy if the potential benefit is felt to outweigh the potential risk to the unborn child. Whether the drug passes into human breast milk is not known, so it should be used with caution in nursing mothers.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: The recommended starting dose is one Febuxostat 40 mg tablet once daily. For patients who do not achieve a serum uric acid level below 6 mg per dL after 2 weeks on Febuxostat 40 mg tablet, one Febuxostat 80 mg tablet once daily is recommended. If serum uric acid remains below 6 mg per dL after 2 to 4 weeks on Xanuric 80 (Febuxostat 80mg) tablet, then one Febuxostat 120 mg tablet once daily is recommended. For Tumor Lysis Syndrome, the recommended dose is one Febuxostat 120 mg tablet once daily. The Febuxostat 120 mg tablet should be started two days before beginning cytotoxic therapy and continued for a minimum of 7 days. Treatment may, however, be prolonged up to 9 days depending on the duration of chemotherapy, based on clinical judgment. Regarding gout flares, these may occur after starting Feboxostat tablets because changing serum uric acid levels can mobilize urate from tissue deposits. Flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended when starting Febuxostat tablets. If a gout flare occurs during treatment, Feboxostat tablets need not be discontinued; the flare should be managed concurrently, as appropriate for the individual patient. In renal impairment, no dose adjustment is necessary when giving Febuxostat to patients with mild to moderate renal impairment. In hepatic impairment, no dose adjustment is necessary in patients with mild to moderate hepatic impairment. For pediatric use, safety and effectiveness in patients under 18 years of age have not been established.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.